甲福明,孕产妇血糖控制和产前类固醇后新生儿低血糖:一项随机临床试验
Enav Yefet1,2, Manal Massalha3,4, Gil Talmon5
1Department of Obstetrics and Gynecology, Tzafon Medical Center, Poriya, Israel.
JAMA network open
|January 9, 2026
概括
在接受贝塔梅他松治疗早产风险的妇女中,甲素有效降低了孕产妇的高血糖和新生儿的低血糖. 这种治疗是安全的,并建议预防产前皮质类固醇的不良影响.
科学领域:
- 产科和妇科 产科和妇科
- 新生儿医学 新生儿医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塔米他用于减少早产并发症,但可能导致孕产妇高血糖和新生儿低血糖.
- 甲福明是一种有效的治疗孕产妇高血糖症,并且已经显示出降低新生儿低血糖症的潜力.
研究的目的:
- 为了评估甲胺对母体血糖控制在贝塔梅他松后的影响.
- 评估早产婴儿新生儿低血糖的发病率,这些婴儿的母亲接受了甲福林.
主要方法:
- 一个多中心的,开放的随机临床试验,涉及接受贝他美的孕妇.
- 参与者被随机分配,在第一次贝他美沙剂量后最多48小时接受甲胺或不接受治疗.
- 监测了母亲的葡萄糖水平,并记录了新生儿低血糖率.
主要成果:
- 甲胺显著降低了母亲的平均葡萄糖值 (总和食后).
- 新生儿低血糖症的发生率在甲福林组明显较低 (21%vs40%).
- 在接受甲福明的妇女中,14%的人报告了轻微的胃肠道不良反应.
结论:
- 甲福明是安全有效的预防贝塔米他诱导的孕产妇高血糖和新生儿低血糖.
- 在接受产前皮质类固醇治疗的妇女中,应考虑服用甲福明以减轻不良影响.
- 这种干预措施改善了早产婴儿及其母亲的结果.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Hypoglycemia and Glucagon
822
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
822
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593


